Short answer
Zymeworks Inc. (ZYME) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $2M (down 91.1% year over year) with net income of −$44M.
Q1 2026 key financials · XBRL
- Revenue
- $2M
- −91.1% YoY
- Net income
- −$44M
- −95.1% YoY
- Operating margin
- -1956.7%
- EPS (diluted)
- −$0.59
- −96.7% YoY
Source: XBRL data from the Zymeworks Inc. (ZYME) Q1 2026 10-Q on SEC EDGAR. USD.
Zymeworks Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New royalty-driven asset aggregation strategy, triggered by strategic shift toward partnering and acquisitions
- Most material update: 100% Section 232 tariff on certain pharmaceutical products beginning September 29, 2026
- BIOSECURE Act restrictions on biotechnology providers of concern, potentially limiting Chinese equipment and services
- Early-stage clinical supplies currently sourced from China, creating near-term tariff and supply-chain exposure
- U.S. Department of Justice Data Security Program restricting sensitive-data transfers involving China and other designated countries
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Zymeworks Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.